The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
MT Newswires on MSN1d
European Equities Close Lower in Tuesday Trading; EU, Euro Area Inflation Rises in OctoberThe European stock markets closed lower in Tuesday trading as The Stoxx Europe fell 0.43%, Germany's DAX was down 0.67%, the FTSE in London was off 0.13%, France's CAC dropped 0.67%, and the Swiss ...
GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...
Some healthcare advocacy groups launched a "Stop RFK War Room" to fight Robert F. Kennedy Jr.'s nomination for HHS Secretary.
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback